Associate Dean for Healthcare Partnerships Dr. Diane Ginsburg was appointed to the Accreditation Council for Pharmacy Education (ACPE) Board of Directors effective July 1, 2024. ACPE is the national agency for the accreditation of professional degree programs in
pharmacy and providers of continuing pharmacy education.
Kimberly J. Long, a Ph.D. candidate in the Dalby Lab in the Division of Chemical Biology and Medicinal Chemistry, was a first author of a recent research paper published in the Proceedings of the National Academy of Sciences (PNAS).
The University of Texas at Austin College of Pharmacy placed in the top ten in the entire country in the percentage of match placements with 91%, compared to the national match placement average of 82%.
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.
Pharmacy schools across the country completed their 2022 Phase I and Phase II residency matches for new or upcoming graduates of their Doctor of Pharmacy (Pharm.D.) programs. The University of Texas at Austin College of Pharmacy placed in the top ten of all pharmacy schools in the nation, and number one in Texas.
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.
Assistant Dean for Experiential and Professional Affairs Jennifer L. Ridings-Myhra, M.Ed., R.Ph. is 2021's recipient of the Distinguished Service Award from the Texas Society of Health-System Pharmacists (TSHP). It is the highest honor TSHP can bestow on an individual.
Dr. Diane Ginsburg has been accepted into the Leadership Texas 2021 class by Leadership Women, Inc. She will represent The University of Texas at Austin during Leadership Texas sessions through November 2021.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.
An update from Dean M. Lynn Crismon regarding the College of Pharmacy’s transition to remote learning and efforts to learn, research, graduate, and stay healthy during the COVID-19 pandemic.